These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29505958)

  • 1. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
    Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
    Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma.
    Vieira GC; Chockalingam S; Melegh Z; Greenhough A; Malik S; Szemes M; Park JH; Kaidi A; Zhou L; Catchpoole D; Morgan R; Bates DO; Gabb PD; Malik K
    Oncotarget; 2015 Nov; 6(37):40053-67. PubMed ID: 26517508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
    Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
    BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma.
    Blanc E; Roux GL; Bénard J; Raguénez G
    Oncogene; 2005 Feb; 24(7):1277-83. PubMed ID: 15592517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Wnt-BMP4 Signaling Axis Induces MSX and NOTCH Proteins and Promotes Growth Suppression and Differentiation in Neuroblastoma.
    Szemes M; Melegh Z; Bellamy J; Greenhough A; Kollareddy M; Catchpoole D; Malik K
    Cells; 2020 Mar; 9(3):. PubMed ID: 32210188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
    Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
    Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
    Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
    Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.
    Revet I; Huizenga G; Koster J; Volckmann R; van Sluis P; Versteeg R; Geerts D
    Cancer Lett; 2010 Mar; 289(2):195-207. PubMed ID: 19815336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
    Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
    Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.